Program
HFA-152a
Its studies are mostly in Asthma, led by GlaxoSmithKline.
Furthest: phase 3, since Jun 8, 20261 company-led study, 1 open or runningNext primary completion: Dec 28, 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 11 open or running | phase 3since Jun 8, 2026 | Jun 8, 2026 | Dec 28, 2026phase 3 · NCT07645248 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 8, 2026First study: phase 3 study in AsthmaFirst studyNCT07645248 · 110 planned · United States, Argentina, Canada and more
Ahead
- Dec 28, 2026Primary completion: phase 3 study in AsthmaNCT07645248
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07645248Asthma · United States, Argentina, Canada and more | 3 | Recruiting | Dec 28, 2026 | 110 |
How it is read
Names in the registry
- “HFA-152a”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.